Skip to main content
. Author manuscript; available in PMC: 2009 Jul 6.
Published in final edited form as: Expert Opin Emerg Drugs. 2009 Jun;14(2):207–217. doi: 10.1517/14728210902946399

Table 2.

Examples of anti-RSV drugs.

Compound Company Structure Indication Stage of
development		 Mechanism
of action
MBX-300 Microbiotix
(USA)		 graphic file with name ukmss-5103-t0001.jpg Infection Discontinued G protein
inhibitor
VP-14637 ViroPharma
(USA)		 graphic file with name ukmss-5103-t0002.jpg Infection Discontinued F protein
inhibitor
RSV-604 Arrow
Therapeutics
(Novartis, UK)		 graphic file with name ukmss-5103-t0003.jpg Phase II
clinical trial		 N protein
inhibitor
RFI-641 Wyeth
(USA)		 graphic file with name ukmss-5103-t0004.jpg Infection,
prophylaxis
prophylaxis		 Discontinued F protein
inhibitor
LY-2 53963 Eli Lilly
(USA)		 graphic file with name ukmss-5103-t0005.jpg Infection Discontinued Unspecified
EICAR Asahi Kasei
Pharma		 graphic file with name ukmss-5103-t0006.jpg Infection Discontinued L-polymerase inhibitor
BMS-433771 Bristol-Myers
Squibb		 graphic file with name ukmss-5103-t0007.jpg Infection Discontinued F protein
inhibitor
ALN-RSV01 Alnylam
(USA)		 RNA Infection,
prophylaxis		 Phase II
clinical trial		 Gene
expression
inhibitor

RSV: Respiratory syncytial virus

HHS Vulnerability Disclosure